Daewoong to put major efforts for entry of urologic market.
Published: 2005-05-24 06:57:00
Updated: 2005-05-24 06:57:00
Daewoong has recently launched Bearfina (finasteride) for the treatment of prostate enlargement by blocking a DHT (dihydrotestosterone) production, a causing molecule of the prostate enlargement, thus initiating an entry of the urological drug markets.
The company says that Bearfina shows an i...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.